Trial Profile

A randomised, double-blind, double-dummy, parallel-group, multi-centre, active-controlled study to evaluate efficacy and safety of fixed dose combination of remogliflozin etabonate and vildagliptin in subjects with type-2 diabetes mellitus. - FOREVER

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Remogliflozin etabonate/vildagliptin (Primary) ; Empagliflozin/linagliptin
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms FOREVER
Sponsors Glenmark Pharmaceuticals Ltd

29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association
19 Jun 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com